ReviewNaunyn-Schmiedeberg's archives of pharmacology2025
Exploiting the cardioprotective potential of metformin against cardiotoxic agents.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decoding cardiac metabolic reprogramming through single-cell multi-omics: from mechanisms to therapeutic applications.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiotoxicity refers to impaired heart function, which can occur either directly or indirectly. The severity of cardiotoxicity depends on age, exposure duration, and the toxic agent involved. Metformin, primarily used in type 2 diabetic patients, exerts its antihyperglycemic effects by improving insulin sensitivity, suppressing hepatic glucose production, and reducing intestinal glucose absorption. Its cardioprotective properties have been demonstrated in several studies. Here, we reviewed the scientific literatures regarding the effect of metformin in preventing heart injury induced by cardiotoxic insults. A comprehensive search of scientific databases, including Web of Science, PubMed, Scopus, and Google Scholar, used relevant keywords to identify studies published up to April 2025. Metformin mitigated cardiotoxicity through various mechanisms, including reducing oxidative stress, increasing AMPK phosphorylation, inhibiting the NF-kB pathway, reducing inflammation, and regulating the autophagy and apoptosis pathways. This study highlights the potential cardioprotective efficacy of metformin against heart injury induced by various cardiotoxic agents.
Indexed as
Identifiers
40524049What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.